Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00567047
First received: December 3, 2007
Last updated: March 24, 2009
Last verified: March 2009

December 3, 2007
March 24, 2009
July 2007
January 2009   (final data collection date for primary outcome measure)
• Pharmacokinetic measures [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00567047 on ClinicalTrials.gov Archive Site
• Safety and tolerability measures [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment
An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate or Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Daily Doses of 50 mg Vildagliptin for 14 Days

This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.

Not Provided
Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Type-2 Diabetes
Drug: vildagliptin
Other Name: LAF237
Experimental: 1
Vildagliptin
Intervention: Drug: vildagliptin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
96
Not Provided
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria (general):

  • Men and women (age 18 to 85 years)
  • Participants must be nonfertile or using a medically approved birth control method. Additional information regarding this requirement available at screening
  • Body mass index (BMI) ≤42 kg/m2 (inclusive)

Inclusion Criteria (for renal insufficient patients):

  • Patients with mild, moderate, or severe kidney impairment. Please consult with participating physicians regarding the definitions of these levels of severity.
  • Patients with diabetes must be treated with standard anti-diabetic therapy (diet and exercise, stable dose of sulfonylurea, insulin, or metiglinides) and agree to continue for the study duration

Inclusion Criteria (for healthy subjects):

  • No current significant medical conditions as determined by history and physical.
  • Serum creatinine with a calculated creatinine clearance (CrCl) of >80 ml/min.
  • Matched to renal impaired patients in the study by age (±5 years), sex and weight (±10% BMI)
  • Vital signs guided by the following ranges:

oral body temperature between 35.0-37.2 °C systolic blood pressure, 100-140 mm Hg diastolic blood pressure, 60-110 mm Hg pulse rate, 45-90 bpm

Exclusion criteria:

  • Pregnant or lactating female.
  • A history of type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, acute metabolic diabetic complications (eg, ketoacidosis or hyperosmolar state (coma))
  • Subjects that have been enrolled in previous vildagliptin studies or other DPP
  • 4 inhibitor studies within six months
  • History of renal transplant or immunosuppressant therapy
  • Acute infections which may affect blood glucose control or other medical condition that may interfere with the interpretation of efficacy and safety data during the study
  • Any pre-existing or history of diabetic ulcer
  • Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery or percutaneous coronary intervention, unstable angina or stroke
  • Any of the following electrocardiogram (ECG) abnormalities: Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation, second degree atrioventricular (AV) block (Mobitz 1 and 2), third degree AV block, prolonged QTc (>500 ms)
  • Malignancy including leukemia and lymphoma within the last 5 years.
  • Liver disease such as cirrhosis or positive hepatitis B and C.
  • Any alcohol related hepatic disease.
  • Patients undergoing any method of dialysis
  • Use of some concomitant medications
  • Significant laboratory abnormalities as specified in the protocol
  • History of active substance abuse (including alcohol) within the past 2 years.
  • Smokers (i.e., 10 or more cigarettes per day)
  • History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures

Other protocol-defined inclusion/exclusion criteria may apply

Both
18 Years to 85 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Germany
 
NCT00567047
CLAF237A2115
No
Novartis
Novartis
Not Provided
Principal Investigator: Novartis Novartis investigative site
Novartis
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP